Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbCellera BiologicsABCL -2.12%53 Cash-to-Debt is 3.98 as of Jun. 2026, which is 58% below its 10-year median of 9.58. GuruFocus rates ABCL with a GF Score™ of 53/100 and a GF Value™ of $4.76 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,371 Biotechnology companies, AbCellera Biologics ranks worse than 57.77% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AbCellera Biologics's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.98.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AbCellera Biologicscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for AbCellera Biologics's Cash-to-Debt or its related term are showing as below:
ABCL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.1 Med: 9.58 Max: 135.33
Current: 3.98
During the past 8 years, AbCellera Biologics's highest Cash to Debt Ratio was 135.33. The lowest was 1.10. And the median was 9.58.
ABCL's Cash-to-Debt is ranked worse than 57.77% of 1371
companies
in the Biotechnology industry
Industry Median: 6.78
vs ABCL: 3.98
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
AbCellera Biologics Cash-to-Debt Related Terms
AbCellera Biologics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, AbCellera Biologics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (ABCL) has a Cash-to-Debt of 3.98 as of Jun. 2026. This is 58% below median its historical median of 9.58. Over the past decade, AbCellera Biologics' Cash-to-Debt has ranged from 1.10 to 135.33. According to the industry distribution chart, AbCellera Biologics ranks #792 out of 1371 companies in the Biotechnology industry, placing it in the top 57.8%.
Is AbCellera Biologics' Cash-to-Debt too high?
AbCellera Biologics' current Cash-to-Debt of 3.98 is 58% below median its 10-year median of 9.58. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 135.33. The Biotechnology industry median Cash-to-Debt is 6.78. AbCellera Biologics' value of 3.98 is 41.3% below this industry median. Based on the distribution chart, AbCellera Biologics ranks #792 out of 1371 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Cash-to-Debt compare to ANAB and MLTX?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #792 out of 1371 companies for Cash-to-Debt. This places AbCellera Biologics in the lower half of its industry. The industry median Cash-to-Debt is 6.78. AbCellera Biologics' value of 3.98 is 41.3% below this benchmark. Historically, AbCellera Biologics' own Cash-to-Debt has ranged from 1.10 to 135.33 over the past decade. While the company's 10-year median is 9.58 vs. the industry median of 6.78, AbCellera Biologics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.78, based on 1,371 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AbCellera Biologics's current Cash-to-Debt of 3.98 is 41.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Cash-to-Debt is 3.98, which is 58% below median its own 10-year median of 9.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.76, compared to a current price of $11.33 — trading 138% above its estimated fair value. The current Cash-to-Debt is 3.98, which is 58% below median its 10-year median of 9.58 and 41.3% below the Biotechnology industry median of 6.78. AbCellera Biologics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Cash-to-Debt is 3.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $11.33 is trading 138% above its estimated GF Value™ of $4.76.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Cash-to-Debt: 3.98 (58% below median its 10-year median of 9.58)
GF Value™: $4.76 vs. price of $11.33 (138% above fair value)
Industry Position: 41.3% below the Biotechnology median (#792 of 1371)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
53GF Score
Get the complete analysis for ABCL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
